Leadership and Management
The Management Committee of the Infectious Diseases and Immunity in Global Health Program (IDIGH) consists of representatives from all three pillars of the program (fundamental, epidemiology and health outcomes, and clinical research), as well as members from outside the program and research trainees. The committee meets three or four times a year to address issues and discuss strategies and action points that move the IDIGH program toward its objective of becoming a leading centre for translational research in infectious and immune-mediated diseases of global importance.
Representatives of fundamental research
Nicole Bernard, PhD
Representatives of graduate students and postdoctoral fellows
Lauren Nagel (co-chair of the IDIGH trainee committee)
Tho-Alfakar Al-Aubodah (co-chair of the IDIGH trainee committee)
External (non-IDIGH program) member
Maziar Divangahi, PhD
|Program leaders and manager
Ciriaco Piccirillo, PhD, is a National Institutes of Health-trained immunologist, a senior scientist in the Infectious Diseases and Immunity in Global Health Program at the Research Institute of the McGill University Health Centre (RI-MUHC), and professor and director of the graduate program in the Department of Microbiology and Immunology at McGill University. He also directs the Centre of Excellence in Translational Immunology (CETI) and the RI-MUHC’s Immunophenotyping Platform, a state-of-the-art technological core facility providing expert advice and training in flow cytometry and cell sorting. He is co-leader of the Immunological and Vaccine Protection pillar of CoVaRR-Net, a national network for the study of the threats of emerging SARS-CoV-2 viral variants.
Prof. Piccirillo leads an internationally recognized research program that focuses on the immune regulation of autoimmune, infectious and inflammatory diseases. His research attempts to harness the power of the immune system to boost, stop or restore T cell function, particularly Foxp3+ regulatory T cells, in autoimmune and inflammatory diseases, cancers or immunodeficiencies. His research is responsible for many seminal and pioneering studies in pre-clinical animal models, non-human primates and humans. His current research program makes use of mouse models and human disease systems to monitor and characterize the development and functional dynamics of T cell function in health and disease and in therapeutic settings. His research also focuses on the development of novel immunotherapeutic strategies to monitor and manipulate Foxp3+ regulatory T cell function and ultimately modulate immune responses in infectious, autoimmune and inflammatory disorders.